{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:54:21Z","timestamp":1774425261265,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Collegium Pharmaceutical Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40122-026-00815-0","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:51:56Z","timestamp":1770547916000},"page":"513-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic and Treatment Burden of Chronic Low-Back Pain Patients Transitioning from Short-Acting to Long-Acting Opioids or Buprenorphine Buccal Film: US Claims Analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-8940","authenticated-orcid":false,"given":"Filip","family":"Stanicic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4962-4396","authenticated-orcid":false,"given":"Dimitrije","family":"Grbic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-4491","authenticated-orcid":false,"given":"Vladimir","family":"Zah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"issue":"2","key":"815_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37371","volume":"4","author":"JM Stevans","year":"2021","unstructured":"Stevans JM, Delitto A, Khoja SS, et al. Risk factors associated with transition from acute to chronic low back pain in us patients seeking primary care. JAMA Netw Open. 2021;4(2):e2037371-e.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"815_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ejp.2146","volume":"27","author":"L Calais-Ferreira","year":"2023","unstructured":"Calais-Ferreira L, Pozzobon D, Pinheiro MB, et al. Sex differences in lifetime prevalence of low back pain: a multinational study of opposite-sex twin pairs. Eur J Pain. 2023;27(10):1150\u201360.","journal-title":"Eur J Pain"},{"issue":"9","key":"815_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jama.2020.0734","volume":"323","author":"JL Dieleman","year":"2020","unstructured":"Dieleman JL, Cao J, Chapin A, et al. Us health care spending by payer and health condition, 1996-2016. JAMA. 2020;323(9):863\u201384.","journal-title":"JAMA"},{"issue":"10","key":"815_CR4","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jpain.2016.06.009","volume":"17","author":"M Von Korff","year":"2016","unstructured":"Von Korff M, Scher AI, Helmick C, et al. United states national pain strategy for population research: concepts, definitions, and pilot data. J Pain. 2016;17(10):1068\u201380.","journal-title":"J Pain"},{"issue":"11","key":"815_CR5","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1007\/s00586-018-5673-2","volume":"27","author":"CB Oliveira","year":"2018","unstructured":"Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791\u2013803.","journal-title":"Eur Spine J"},{"key":"815_CR6","unstructured":"North American Spine Society (NASS). Evidence-based clinical guidelines for multidisciplinary spine care: Diagnosis and treatment of low back pain. Updated Aug 10, 2020. https:\/\/www.spine.org\/Portals\/0\/assets\/downloads\/ResearchClinicalCare\/Guidelines\/LowBackPain.pdf. Cited 2 Apr 2025."},{"key":"815_CR7","unstructured":"Department of Veteran Affairs and Department of Defense (VA\/DoD). A\/dod clinical practice guideline for the diagnosis and treatment of low back pain v3. Updated May\u00a011, 2023. https:\/\/www.healthquality.va.gov\/guidelines\/pain\/lbp\/. Cited 2 Apr 2025."},{"key":"815_CR8","doi-asserted-by":"crossref","unstructured":"Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G. Clinical guidelines for the management of low back pain in primary care: an international comparison. Spine (Phila Pa 1976). 2001;26(22):2504\u201313 (discussion 13\u20134).","DOI":"10.1097\/00007632-200111150-00022"},{"issue":"11","key":"815_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/bjsports-2018-099805","volume":"54","author":"HR Tucker","year":"2020","unstructured":"Tucker HR, Scaff K, McCloud T, et al. Harms and benefits of opioids for management of non-surgical acute and chronic low back pain: a systematic review. Br J Sports Med. 2020;54(11):664.","journal-title":"Br J Sports Med"},{"issue":"1","key":"815_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","volume":"65","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1\u201349.","journal-title":"MMWR Recomm Rep"},{"key":"815_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","volume":"3","author":"KM Keyes","year":"2022","unstructured":"Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"3","key":"815_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"D Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. Cdc clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395.","journal-title":"MMWR Recomm Rep"},{"issue":"null","key":"815_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.2147\/JMDH.S449748","volume":"17","author":"J Adler","year":"2024","unstructured":"Adler J, Theresa M-S, Mark G, Zimmerman A. Frontline perspectives on buprenorphine for the management of chronic pain. J Multidiscip Healthc. 2024;17(null):1375\u201383.","journal-title":"J Multidiscip Healthc"},{"key":"815_CR14","unstructured":"Drug Enforcement Administration - Diversion Control Division - Drug & Chemical Evaluation Section. Buprenorphine. Updated May\u00a02022. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/buprenorphine.pdf. Cited 2 Apr 2025."},{"key":"815_CR15","unstructured":"Drug Enforcement Administration - Department of Justice. Schedules of controlled substances: Rescheduling of buprenorphine from schedule v to schedule iii. https:\/\/www.federalregister.gov\/documents\/2002\/10\/07\/02-25293\/schedules-of-controlled-substances-rescheduling-of-buprenorphine-from-schedule-v-to-schedule-iii. Cited 2 Apr 2025."},{"issue":"1","key":"815_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","volume":"9","author":"J Gudin","year":"2020","unstructured":"Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41\u201354.","journal-title":"Pain Ther"},{"issue":"1","key":"815_CR17","doi-asserted-by":"publisher","DOI":"10.52965\/001c.27241","volume":"9","author":"S Dalal","year":"2021","unstructured":"Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for chronic pain: a safer alternative to traditional opioids. Health Psychol Res. 2021;9(1):27241.","journal-title":"Health Psychol Res"},{"issue":"11","key":"815_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1097\/j.pain.0000000000000670","volume":"157","author":"J Gimbel","year":"2016","unstructured":"Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase\u00a03, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517\u201326.","journal-title":"Pain"},{"issue":"Suppl 1","key":"815_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The strobe guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31\u20134.","journal-title":"Saudi J Anaesth"},{"key":"815_CR20","unstructured":"Merative. IBM marketscan research databases is now merative\u2122 marketscan\u00ae research databases. https:\/\/www.merative.com\/real-world-evidence. Cited 2 Apr 2025."},{"issue":"7","key":"815_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/M16-2367","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514\u201330.","journal-title":"Ann Intern Med"},{"key":"815_CR22","unstructured":"Centers for Disease Control and Prevention (CDC). Chronic pain among adults\u2014United States, 2019\u20132021. Updated Apr 13, 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7215a1.htm. Cited 17 Dec 2025."},{"issue":"4","key":"815_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17581869.2024.2348989","volume":"14","author":"V Zah","year":"2024","unstructured":"Zah V, Stanicic F, Vukicevic D, Grbic D. Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain. Pain Manag. 2024;14(4):195\u2013207.","journal-title":"Pain Manag"},{"key":"815_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2147\/JPR.S130913","volume":"10","author":"PB Landsman-Blumberg","year":"2017","unstructured":"Landsman-Blumberg PB, Katz N, Gajria K, et al. Health care resource use and cost differences by opioid therapy type among chronic noncancer pain patients. J Pain Res. 2017;10:1713\u201322.","journal-title":"J Pain Res"},{"issue":"1","key":"815_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pmt-2023-0124","volume":"14","author":"F Stanicic","year":"2024","unstructured":"Stanicic F, Grbic D, Vukicevic D, Zah V. Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch. Pain Manag. 2024;14(1):35\u201348.","journal-title":"Pain Manag"},{"issue":"1","key":"815_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00325481.2016.1128307","volume":"128","author":"RL Rauck","year":"2016","unstructured":"Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1\u201311.","journal-title":"Postgrad Med"},{"issue":"5","key":"815_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/pm\/pnaa226","volume":"22","author":"A Zimmerman","year":"2020","unstructured":"Zimmerman A, Bikdash R, Rauck R. Conversion of Schedule\u00a0II opioids to buprenorphine buccal film: a retrospective analysis. Pain Med. 2020;22(5):1109\u201315.","journal-title":"Pain Med"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00815-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:07:38Z","timestamp":1774418858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00815-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00815-0","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filip Stanicic, Dimitrije Grbic, and Vladimir Zah are employees of ZRx Outcomes Research Inc. ZRx Outcomes Research Inc. received funding from Collegium Pharmaceutical Inc. for conducting this study. The funding source did not have any direct or indirect impact on study findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Merative MarketScan\n                      \u00ae\n                      insurance claims database used for this analysis complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), protecting patients\u2019 privacy and ensuring the confidentiality of personal data. Since all data within the abovementioned database are de-identified, approval of the institutional review board or the ethics committee for conducting the research was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}